Myeloproliferative Neoplasms
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed…
Date: 22nd December 2023
MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches
The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years,…
Date: 10th November 2023
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
Patients with BCR-ABL negative myeloproliferative neoplasms (MPNs) are at risk of progressing to accelerated-phase or blast-phase disease (MPN-AP/BP). Several mutations, including…
Date: 10th August 2023
The importance of addressing quality of life and improving symptom management in MPNs
Myeloproliferative neoplasms (MPNs) represent a challenging group of diseases to treat, and patients with MPNs suffer from several symptoms which…
Date: 19th July 2023
The current role of stem cell transplantation in MPNs & how this may change with novel agents
Myeloproliferative neoplasms (MPNs) represent a heterogeneous group of diseases which remain a challenge to treat. While there have been several…
Date: 27th April 2023
MPN highlights at ASH 2022: novel agents, combinations & the role of immunotherapy
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA,…
Date: 26th January 2023
Highlights from the 2022 Texas MPN Workshop: early intervention, disease progression & future targets
The 2022 Texas MPN Workshop was held in San Antonio, TX, and covered several fascinating topics in the field of…
Date: 7th October 2022
Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment
Myeloproliferative neoplasms (MPNs) represent a group of rare and heterogeneous diseases which remain a challenge to treat. Several advances have…
Date: 9th September 2022
Key updates in the treatment and management of MPNs
Myeloproliferative neoplasms (MPNs) are a class of hematological cancers characterized by the excessive production of a particular blood cell. MPNs…
Date: 8th July 2022
ASH 2021: novel developments in MPNs
The JAK-STAT pathway plays a pivotal role in the pathogenesis of myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and…
Date: 11th March 2022
Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs
Janus kinase (JAK) inhibitors are becoming an increasingly prominent class of drug in the treatment of myeloproliferative neoplasms (MPNs), in…
Date: 3rd September 2021
Texas MPN Workshop 2021: updates on interferons for MPNs
Many clinical trials are currently investigating the potential benefits of interferons in the treatment of myeloproliferative neoplasms (MPNs), in particular…
Date: 27th August 2021
